Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Hiroshi Saeki, Yuichiro Nakashima, Yoko Zaitsu, Yasuo Tsuda, Yuta Kasagi, Kouji Andou, Yu Imamura, Kippei Ohgaki, Shuhei Ito, Yasue Kimura, Akinori Egashira, Eiji Oki, Masaru Morita, Yoshihiko Maehara

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The significance of neoadjuvant chemoradiotherapy (NACRT) for esophageal squamous cell carcinoma (ESCC) remains controversial with regard to the pathological response and long-term survival. We herein review the current status of and future perspectives regarding NACRT followed by esophagectomy for locally advanced ESCC. Some studies have suggested that a pathological complete response with NACRT is more common in patients with ESCC than in those with adenocarcinoma and that NACRT provided a survival benefit limited to patients with ESCC. However, NACRT may increase the risk of postoperative complications after esophagectomy. It is obvious that a favorable pathological response is the most important factor for obtaining a survival benefit, although no established parameters have been implemented clinically to predict the response to NACRT. Prospective clinical studies and basic research studies to identify predictive biomarkers for the response to NACRT are needed to aid in the development of NACRT treatment strategies for patients with ESCC.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalSurgery today
Volume46
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Chemoradiotherapy
Esophagectomy
Survival
Neoadjuvant Therapy
Esophageal Squamous Cell Carcinoma
Adenocarcinoma
Biomarkers
Prospective Studies
Research

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. / Saeki, Hiroshi; Nakashima, Yuichiro; Zaitsu, Yoko; Tsuda, Yasuo; Kasagi, Yuta; Andou, Kouji; Imamura, Yu; Ohgaki, Kippei; Ito, Shuhei; Kimura, Yasue; Egashira, Akinori; Oki, Eiji; Morita, Masaru; Maehara, Yoshihiko.

In: Surgery today, Vol. 46, No. 3, 01.03.2016, p. 261-267.

Research output: Contribution to journalReview article

Saeki, Hiroshi ; Nakashima, Yuichiro ; Zaitsu, Yoko ; Tsuda, Yasuo ; Kasagi, Yuta ; Andou, Kouji ; Imamura, Yu ; Ohgaki, Kippei ; Ito, Shuhei ; Kimura, Yasue ; Egashira, Akinori ; Oki, Eiji ; Morita, Masaru ; Maehara, Yoshihiko. / Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. In: Surgery today. 2016 ; Vol. 46, No. 3. pp. 261-267.
@article{348f593b621c4243bc6302768fa3b2e4,
title = "Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma",
abstract = "The significance of neoadjuvant chemoradiotherapy (NACRT) for esophageal squamous cell carcinoma (ESCC) remains controversial with regard to the pathological response and long-term survival. We herein review the current status of and future perspectives regarding NACRT followed by esophagectomy for locally advanced ESCC. Some studies have suggested that a pathological complete response with NACRT is more common in patients with ESCC than in those with adenocarcinoma and that NACRT provided a survival benefit limited to patients with ESCC. However, NACRT may increase the risk of postoperative complications after esophagectomy. It is obvious that a favorable pathological response is the most important factor for obtaining a survival benefit, although no established parameters have been implemented clinically to predict the response to NACRT. Prospective clinical studies and basic research studies to identify predictive biomarkers for the response to NACRT are needed to aid in the development of NACRT treatment strategies for patients with ESCC.",
author = "Hiroshi Saeki and Yuichiro Nakashima and Yoko Zaitsu and Yasuo Tsuda and Yuta Kasagi and Kouji Andou and Yu Imamura and Kippei Ohgaki and Shuhei Ito and Yasue Kimura and Akinori Egashira and Eiji Oki and Masaru Morita and Yoshihiko Maehara",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00595-015-1144-0",
language = "English",
volume = "46",
pages = "261--267",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

AU - Saeki, Hiroshi

AU - Nakashima, Yuichiro

AU - Zaitsu, Yoko

AU - Tsuda, Yasuo

AU - Kasagi, Yuta

AU - Andou, Kouji

AU - Imamura, Yu

AU - Ohgaki, Kippei

AU - Ito, Shuhei

AU - Kimura, Yasue

AU - Egashira, Akinori

AU - Oki, Eiji

AU - Morita, Masaru

AU - Maehara, Yoshihiko

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The significance of neoadjuvant chemoradiotherapy (NACRT) for esophageal squamous cell carcinoma (ESCC) remains controversial with regard to the pathological response and long-term survival. We herein review the current status of and future perspectives regarding NACRT followed by esophagectomy for locally advanced ESCC. Some studies have suggested that a pathological complete response with NACRT is more common in patients with ESCC than in those with adenocarcinoma and that NACRT provided a survival benefit limited to patients with ESCC. However, NACRT may increase the risk of postoperative complications after esophagectomy. It is obvious that a favorable pathological response is the most important factor for obtaining a survival benefit, although no established parameters have been implemented clinically to predict the response to NACRT. Prospective clinical studies and basic research studies to identify predictive biomarkers for the response to NACRT are needed to aid in the development of NACRT treatment strategies for patients with ESCC.

AB - The significance of neoadjuvant chemoradiotherapy (NACRT) for esophageal squamous cell carcinoma (ESCC) remains controversial with regard to the pathological response and long-term survival. We herein review the current status of and future perspectives regarding NACRT followed by esophagectomy for locally advanced ESCC. Some studies have suggested that a pathological complete response with NACRT is more common in patients with ESCC than in those with adenocarcinoma and that NACRT provided a survival benefit limited to patients with ESCC. However, NACRT may increase the risk of postoperative complications after esophagectomy. It is obvious that a favorable pathological response is the most important factor for obtaining a survival benefit, although no established parameters have been implemented clinically to predict the response to NACRT. Prospective clinical studies and basic research studies to identify predictive biomarkers for the response to NACRT are needed to aid in the development of NACRT treatment strategies for patients with ESCC.

UR - http://www.scopus.com/inward/record.url?scp=84957426406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957426406&partnerID=8YFLogxK

U2 - 10.1007/s00595-015-1144-0

DO - 10.1007/s00595-015-1144-0

M3 - Review article

C2 - 25740123

AN - SCOPUS:84957426406

VL - 46

SP - 261

EP - 267

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 3

ER -